CytoCore Announces Major Institutional Investor Converts Note to Stock.

CHICAGO -- CytoCore, Inc. (OTCBB:MCDG) today announced that a large European institutional investor in CytoCore, Monsun AS, has chosen to convert its note into equity in the Company.

CytoCore's CFO Robert McCullough Jr. stated, "We are very pleased with the decision by Monsun to convert. They have been a long term note holder in the Company, and their conversion helps us on a number of fronts. Their conversion eliminates a substantial amount of debt in our restructuring and cleanup work which helps strengthen the balance sheet. Also, its a strong statement of their support in the progress we've made. We look forward to their continued proactive support for CytoCore as we move forward."

A representative of Monsun AS stated: "We are now comfortable to convert our preferred position in CytoCore into common stock thereby expressing our confidence in and support of the current management team. We believe the new team at CytoCore has done a great job over the past nine months. Management is, in our view, taking the right steps to bring the company's expanding technology base and product opportunities rapidly to the market. We originally invested in CytoCore based on our assessment of the market potential of its unique molecular diagnostic testing platform, which we believe has the potential to change the way a number of different cancers, including cervical and uterine cancers, are screened for, diagnosed and treated in the future. We express this vote of confidence in the current management team after having followed closely the successful financial and operative turn-around process initiated last year. We are impressed and obviously pleased with management's ability to execute and deliver on its key operative milestones in a timely fashion. We believe the next 12 months will be very crucial and exiting for the company leading to significant value creation for all shareholders."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005 and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.